Calendar

««Jul 2008»»
SMTWTFS
  
1
2
3
4
5
6789101112
13141516171819
20212223242526
2728293031

Search Box

 


HealthCentral Top Site Award

IBS Tales Hope Award
  More

Mailing List

RSS Feeds








Widgetize!

Translation

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

recommended links

Depression is Real's Down & Up Show
      Weekly audio-casts from the
      Depression Is Real Coalition

we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 1,537,009
since: 14 May 2006

Antidepressant benefit may be apparent sooner

posted Tuesday, 18 July 2006

Timothy F. Kirn

TORONTO - Most clinical recommendations advise that patients who start an antidepressant be given 4-6 weeks to see whether they respond and have improvement.

But an analysis of more than 5,000 patients treated in clinical trials with a variety of antidepressants suggests that most patients who respond well start to improve within 2 weeks, Dr. Armin Szegedi said at the annual meeting of the American Psychiatric Association.

"This is a very strong, clinically relevant, and, perhaps to many, a surprising finding," said Dr. Szegedi, executive director of clinical projects, psychiatry, at Organon International Inc., Rosalind, N.J., in an interview.

The analysis included patients who were treated with six different, selective serotonin reuptake inhibitors, including paroxetine (Paxil) and fluoxetine; two tricyclic antidepressants, amitriptyline and doxepin; and venlafaxine (Effexor), a selective norepinephrine reuptake inhibitor.

More...

© 2006 Elsevier Inc. All rights reserved

tags:        

links: digg this    del.icio.us    technorati    reddit